News Kidney biotech R1's $78m debut, and other biofinancings Biofinancing values have tailed off a bit after a strong start to 2026, but March has seen $50m+ rounds for R1, Crossbow, Excalipoint, and Prolium.
News Astellas bets on Vir cancer drug, and other licensing deals Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.
News Insmed partners patient group on bronchiectasis study Insmed is working with a bronchiectasis patient organisation on a real-world trial of Brinsupri, the first FDA-approved drug for the lung disorder.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.